Etoricoxib shortage — NL supply status & alternatives

Etoricoxib

ATC M01AH05

🇦🇺 AUST R 204147

In supply · Australia

AlgixEtoricoxib Viatris

In supply · 🇦🇺 Australia · short in🇩🇪 DE🇪🇸 ES🇮🇹 IT🇧🇪 BE🇮🇪 IE🇳🇱 NL

In supply in Australia

Reading today’s signals…

✓ Can I substitute?

Per normal rules

Confirm with prescriber

⇄ Best alternative

Ibuprofen

◷ Expected back

No estimate

No estimate provided

Product attributes reference data we hold

Brand names	Algix, Etoricoxib Viatris

ATC level 5	M01AH05

ATC level 4	M01AH

Therapeutic category	Auto-created by Agenzia Italiana del Farmaco — Carenze scraper

Controlled substance	No

Marketing-authorisation holders	TEVA UK LIMITED, KRKA, TOVARNA ZDRAVIL, D.D., NOVO MESTO, Generics (UK) Limited, Cipla Australia Pty Ltd +1 more

Registrations on file	15

Patient information leaflet (PIL)	Not on file

Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 Australia · awaiting price ingest

🇦🇺 AU

Ex-manufacturer

—

Dispensed (DPMQ)

—

Pack

—

Not yet captured for Australia

Official pricing isn’t on file for this market yet. PBS (Australia), NHS Drug Tariff (United Kingdom) and CMS NADAC (United States) feeds are prioritised; this panel populates automatically once the data lands.

Other markets

🇬🇧 GB

£1.79

concession

🇮🇹 IT

€9.01

Retail price

🇪🇸 ES

€10.74

Retail price

Substitution pathways 🇦🇺 Australia · TGA

—

No substitution instrument in force

Dispense per normal rules, or refer to the prescriber. No active SSSI/S19A instrument detected for this medicine.

Global API supply base 🇺🇸 FDA Drug Master Files · active Type II

3 API manufacturers

Manufacturers with an active Type II Drug Master File — i.e. cleared to supply this active ingredient into the US market. A proxy for how concentrated the global manufacturing base is.

High concentration risk

Hetero Labs LTDAlembic Pharmaceuticals LTDMetrochem Api Private LTD

Manufacturing countries: India · Source: FDA List of Drug Master Files

Shortage status by regulator official notices

🇮🇪

Ireland

HPRA · 1h ago

Medium

🇳🇱

Netherlands

CBG-MEB · 2h ago

Medium

🇮🇹

Italy

AIFA · 4h ago

Medium

🇧🇪

FAMHP · 9d ago

Medium

🇩🇪

Germany

BfArM · 10d ago

Medium

🇪🇸

Spain

AEMPS · 1mo ago

Medium

Verified timeline regulator events

🇮🇹 1 Nov 2026

medium reported

🇮🇹 31 Oct 2026

medium reported

🇮🇹 18 Aug 2026

medium reported

🇮🇹 15 July 2026

medium reported

🇳🇱 1 July 2026

medium reported

🇮🇪 30 June 2026

medium reported

Sources official regulators

🇮🇪

HPRA

verified 1h ago

verify ↗

🇳🇱

CBG-MEB

verified 2h ago

verify ↗

🇮🇹

AIFA

verified 4h ago

verify ↗

🇧🇪

FAMHP

verified 9d ago

verify ↗

🇩🇪

BfArM

verified 10d ago

verify ↗

🇪🇸

AEMPS

verified 1mo ago

verify ↗

Registration recordmarketing-authorisation holders

Registrations & marketing-authorisation holders15 registrations · 5 MA holders

Product	Strength	Form	Market	MA holder	Status
ARCOXIA etoricoxib	90mg	—	🇦🇺 AU	—	Active
ETORICOXIB 30MG FILM-COATED TABLETS	30MG	tablet	🇬🇧 GB	TEVA UK LIMITED	Active
ETORICOXIB 60MG FILM-COATED TABLETS	60MG	tablet	🇬🇧 GB	TEVA UK LIMITED	Active
ETORICOXIB 90 MG FILM-COATED TABLETS	90 MG	tablet	🇬🇧 GB	TEVA UK LIMITED	Active
ETORICOXIB 120MG FILM-COATED TABLETS	120MG	tablet	🇬🇧 GB	TEVA UK LIMITED	Active
ETORICOXIB 30 MG FILM-COATED TABLETS	30 MG	tablet	🇬🇧 GB	KRKA, TOVARNA ZDRAVIL, D.D., NOVO MESTO	Active
ETORICOXIB 60 MG FILM-COATED TABLETS	60 MG	tablet	🇬🇧 GB	KRKA, TOVARNA ZDRAVIL, D.D., NOVO MESTO	Active
ETORICOXIB 120 MG FILM-COATED TABLETS	120 MG	tablet	🇬🇧 GB	KRKA, TOVARNA ZDRAVIL, D.D., NOVO MESTO	Active
Etoricoxib Mylan	30 MG	tablet	🇬🇧 GB	Generics (UK) Limited	Active
Etoricoxib Mylan	60 MG	tablet	🇬🇧 GB	Generics (UK) Limited	Active
Etoricoxib Mylan	90 MG	tablet	🇬🇧 GB	Generics (UK) Limited	Active
Etoricoxib Mylan	120 MG	tablet	🇬🇧 GB	Generics (UK) Limited	Active
ETORICIP etoricoxib	120 mg	—	🇦🇺 AU	Cipla Australia Pty Ltd	Active
E-COXIP etoricoxib	120 mg	—	🇦🇺 AU	Cipla Australia Pty Ltd	Active
ETORICOXIB 90MG FILM-COATED TABLETS	90MG	tablet	🇬🇧 GB	ZENTIVA PHARMA UK LIMITED	Active

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.